MPMilene Machado Paz

Milene Machado Paz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Milene Machado Paz has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determining factors of non-fibrocystic bronchiectasis in patients from southern Brazil: pilot study

    by Daniel Olmedo, Dara Biatobock, Alessandra Galski Rosiak, Eduarda Luza, Linjie Zhang, Marieli Cristina Ribeiro, Milene Machado Paz, Karine Ortiz Sanchotene, Melissa Orzechowski Xavier, Pedro Eduardo Almeida Da Silva, et al.

    Introduction: Bronchiectasis is a chronic respiratory disease that is largely related to inflammatory processes, irreversible dilation of the bronchi and the presence of recurrent lung infections. Furthermore, the disease presents a wide geographic, prevalence and etiological variability, driving the need for local assessments that aim to understand the disease and its behavior in different regions of the world. Objective: To carry out a first approach to the prevalence profile of the disease in the extreme south of Brazil. Method: Census study evaluating the clinical, sociodemographic profile and prevalence of bronchiectasis in patients treated at a regional reference pulmonology outpatient clinic. Result: Of the 95 patients eligible for the study, 21 were classified as bronchiectatic through tomographic diagnosis. The majority of patients were women (67%), caucasian (86%), and aged between 61 and 80 years (62%). Regarding the diseases and symptoms reported by patients, a considerable presence of post-tuberculosis patients (40%) could be identified. Furthermore, the performance of pneumococcal vaccination was also a variable that showed a significant difference, where 55% of diagnosed patients did not undergo vaccination. Conclusion: This study allows the development of a population-based study, guiding health policies that favor the monitoring and quality of life of these patients

  • Open Access

    Response to letter to the editor: Comment on “Mutagenic damage among bronchiectasis patients attending in the pulmonology sector of a hospital in southern Brazil”

    by Daniela Fernandes Ramos, Daniel Wenceslau Votto Olmedo, Katheryne Benini Martins, Milene Machado Paz, Caroline Lopes Feijo Fernandes, Flavio Manoel Rodrigues da Silva Júnior

  • Open Access

    Mutagenic damage among bronchiectasis patients attending in the pulmonology sector of a hospital in southern Brazil

    by Daniel Wenceslau Votto Olmedo, Katheryne Benini Martins, Milene Machado Paz, Caroline Lopes Feijo Fernandes, Flavio Manoel Rodrigues da Silva Júnior, Daniela Fernandes Ramos

    OBJECTIVE: Bronchiectasis is a chronic respiratory disease characterized by inflammation, irreversible dilation of the bronchi, and recurrent pulmonary infections, with a high morbidity and mortality rate, but is less studied from the point of view of its prevalence and associated factors not directly related to respiratory prognosis. As it is a disease related to the exacerbation of the inflammatory process and oxidative stress, this study searched to investigate the micronucleus frequency in patients with and without bronchiectasis treated at a specialized pulmonology service in a hospital in the extreme south of Brazil.METHODS: Patients with a confirmed tomographic diagnosis of bronchiectasis were defined as cases. Mutagenicity was evaluated by the micronucleus test in patients' oral mucosa cells. Data collection was performed through a questionnaire containing socioeconomic, demographic, lifestyle, and health condition information.RESULTS: Of the 95 patients involved in this study, 21 (22.1%) were diagnosed with bronchiectasis aged between 12 and 89 years. There was no significant difference in the frequency of micronucleus between patients with and without bronchiectasis. There was a significant positive association between age and frequency of micronucleus among patients with bronchiectasis, but this association does not occur among patients without the disease.CONCLUSION: This is the first study to investigate data on the prevalence and clinical and epidemiological aspects of this chronic disease in Brazil, especially those related to the genotoxicity outcome.


  • Open Access

    Bronchiectasis: morbidity and mortality in Brazil and its impact on hospitalization rates

    by Dara Biatobock, Milene da Silva Machado Paz, Daniel Wenceslau Votto Olmedo, Edison Luiz Devos Barlem, Daniela Fernandes Ramos

    Objective: To evaluate the morbidity and mortality of bronchiectasis, its interface with the maintenance of hospitalization rates and unsatisfactory prognostic outcomes, as well as the negative impact on Brazilian public health. Methods: The clinical and epidemiological information came from the IT department of the Brazilian Unified Health System - DataSus, from which the required data was filtered through the SUS - CID10 list of morbidities. Information was sought, in absolute numbers, regarding the hospitalization of bronchiectasis patients, such as gender, age, time and cost of hospitalization, care regime, and the number of deaths due to the disease. Results: From the variables found, it was noted that in the period from January 2008 to February 2020, around 24,087 bronchiectasis patients were hospitalized. 65% of the total number of hospitalizations due to the disease consisted of adults, with a large portion in the productive phase (between 20 and 79 years). 84% of the patients sought health units in an emergency mode and 47% used public services at the time of hospitalization. The Brazilian average length of stay in hospital was estimated at 8.1 days and the cost of the service was around R$ 28 million in the twelve years analyzed. Besides, 698 deaths due to bronchiectasis were recorded in Brazil. Conclusions: Diseases such as bronchiectasis are far from the adequate management that chronic lung diseases require. Despite the significant diagnostic evolution, the etiology and treatment of disease is still questionable, providing unsatisfactory quality of life for bronchiectasis patients.